Shares of Hims & Hers Health Inc. experienced a sharp decline on Tuesday, closing down 22% after the telehealth company released its fourth-quarter financial results. The release has raised concerns among investors regarding the potential impact of its weight-loss drug business on overall profit margins.

In its earnings report, Hims & Hers outlined the performance of its various segments, highlighting its telehealth services, as well as its recent ventures into weight management pharmaceuticals. While the company has seen growth in users and increased revenue, uncertainty surrounding the profitability of its weight-loss drugs led to scrutiny. Analysts noted that high development costs and competitive market pressures could significantly affect margins, particularly in an increasingly crowded sector.

The decline in Hims & Hers shares is part of a broader trend in the markets, as investors react to earnings reports and economic indicators. The company’s drop comes amid a challenging landscape for telehealth providers, who are navigating evolving consumer behaviors and regulatory considerations.